Syndax Pharmaceuticals (SNDX) Expected to Announce Quarterly Earnings on Monday

Syndax Pharmaceuticals (NASDAQ:SNDX) will likely be issuing its Q3 2025 results after the market closes on Monday, November 3rd. Analysts expect the company to announce earnings of ($0.73) per share and revenue of $49.0840 million for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Monday, November 3, 2025 at 4:30 PM ET.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.01) by $0.18. The company had revenue of $37.96 million for the quarter, compared to the consensus estimate of $26.64 million. Syndax Pharmaceuticals had a negative net margin of 428.48% and a negative return on equity of 130.47%. The firm’s revenue was up 984.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.80) earnings per share. On average, analysts expect Syndax Pharmaceuticals to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Syndax Pharmaceuticals Stock Performance

SNDX opened at $13.70 on Friday. The company has a current ratio of 4.71, a quick ratio of 4.55 and a debt-to-equity ratio of 2.06. The company has a market cap of $1.18 billion, a price-to-earnings ratio of -3.52 and a beta of 0.68. The company’s 50 day moving average is $15.37 and its 200 day moving average is $12.55. Syndax Pharmaceuticals has a 12-month low of $8.58 and a 12-month high of $22.50.

Wall Street Analyst Weigh In

SNDX has been the topic of a number of research reports. B. Riley raised shares of Syndax Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, August 6th. UBS Group dropped their price objective on shares of Syndax Pharmaceuticals from $37.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, July 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Syndax Pharmaceuticals in a report on Wednesday, October 8th. Stifel Nicolaus began coverage on shares of Syndax Pharmaceuticals in a report on Wednesday, September 10th. They set a “buy” rating and a $44.00 price target on the stock. Finally, Citigroup lifted their price target on shares of Syndax Pharmaceuticals from $46.00 to $51.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Syndax Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $38.00.

Insider Activity at Syndax Pharmaceuticals

In other news, CEO Michael A. Metzger sold 157,307 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $16.41, for a total transaction of $2,581,407.87. Following the sale, the chief executive officer owned 298,661 shares in the company, valued at $4,901,027.01. This trade represents a 34.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Dennis Podlesak sold 19,200 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $15.84, for a total transaction of $304,128.00. Following the sale, the director owned 191,763 shares in the company, valued at approximately $3,037,525.92. The trade was a 9.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 195,707 shares of company stock worth $3,183,904 in the last ninety days. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of SNDX. AQR Capital Management LLC raised its position in shares of Syndax Pharmaceuticals by 478.8% during the first quarter. AQR Capital Management LLC now owns 377,444 shares of the company’s stock valued at $4,637,000 after buying an additional 312,231 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Syndax Pharmaceuticals by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,842 shares of the company’s stock valued at $705,000 after buying an additional 3,094 shares during the last quarter. Caxton Associates LLP bought a new stake in shares of Syndax Pharmaceuticals during the first quarter valued at approximately $257,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Syndax Pharmaceuticals by 18.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 200,696 shares of the company’s stock valued at $2,466,000 after buying an additional 30,596 shares during the last quarter. Finally, Legal & General Group Plc raised its position in shares of Syndax Pharmaceuticals by 4.9% during the second quarter. Legal & General Group Plc now owns 84,575 shares of the company’s stock valued at $792,000 after buying an additional 3,937 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).